Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alcohol dehydrogenase class-3 (ADH5), also known as formaldehyde dehydrogenase and S-nitrosoglutathione reductase, is an enzyme of the medium-chain dehydrogenase/reductase family. It primarily catalyzes the glutathione-dependent oxidation of formaldehyde and the reduction of S-nitrosoglutathione, playing a key role in detoxification of these reactive metabolites[1][3][5]. In humans, the enzyme forms a homodimer with each subunit binding two zinc atoms, essential for structural stability and catalysis. ADH5 is widely expressed and localizes to both the cytoplasm and nucleus. Unlike other alcohol dehydrogenases, it does not efficiently metabolize ethanol or retinoids. Its activity is crucial for cellular defense against formaldehyde-induced DNA damage, maintenance of S-nitrosothiol balance, and nitrogen oxide metabolism[1][5]. Dysfunction or genetic variation in ADH5 has been implicated in increased susceptibility to formaldehyde toxicity, carcinogenesis, and disorders involving redox imbalance[1][3][5].
Inhibition of the enzymatic oxidation of formaldehyde; Blockade of S-nitrosoglutathione reduction
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alcohol dehydrogenase class-3 (ADH5).